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Abstract
Liposome-mediated drug delivery systems alongwith other newer approaches of drug targeting have
revolutionized the measures of controlling parasitic infections, including, malaria. leishmania. fungal
infections, besides providing a new approach to control several bacterial infections, including
Mycobacterial. Salmonella. Pseudomonas. etc., some of which have acquired resistance. These
approaches provide definite reduction in drug toxicity. specially in leishmaniasis and control of
candidiasis and other pathogenic fungi. Liposomal drugs. like amphotericin-B. would have extensive
use in the management of fungal diseases. Liposome mediated drug delivery has an exceptional
advantage ofbiocompatibility. biodegradability. non-immunogenicity and can be used in clinical cases
without any side-effects.
(Key words: liposomes/drug delivery/parasites/fungal infections! T.B.)
Introduction
Pathogens have been with us since our existence and the diseases once thought to be
conquered or under control have again gathered momentum. This is primarily because of
the lacklustre performance of their control measures and the constant evolutionary pressures
put up by the microbes on their hosts; recent examples being the emergence of drug
resistancel. current global estimates of some of the ravaging diseases, e.g, malaria,
leishmaniasis, tuberculosis etc., are alarming, emphasizing the importance of their effective
treatment and controI2-4.
The last decade has seen a spurt in development of means to deliver antimicrobial
agents/drugs to their intended sites of a~lion in the body. Liposomes. first described in
early sixties5.have been extensively investigated fortheirpotential as drug carriers6. Because
of certain exquisite properties of liposomes. such as biocompatibility, biodegradability,
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nonimmunogenicity and versatility in structural constituents, immunerable attempts have
been made to use liposomes as drug/enzyme/antigen carriers in biology and medicine. The
objectives of this review are two fold: firstly, to summarize various fascinating
characteristics of liposomes which make them suitable for use as carriers for drug targeting
and secondly, to provide a comprehensive account of the various attempts that have been
made to use Iiposome-based drug delivery systems in treatment of infectious diseases.
Liposomes as drug carriers
Liposomes are spherically closed concentric bilayers which are separated by aqueous
compartments, and are formed upon dispersing phospholipids in water. Their major
constituents may include natural (phosphatidylcholine, phosphatidylserine, phosphatidyl-
glycerol, cardiolipin, sphingomyelin) or' synthetic (dipalmitoylphosphatidylcholine,
stearylamine derivatives, dicetylphosphate derivatives) phospholipids, sterols (cholesterol,
ergosterol) fatty acids, glycolipids and proteins7. Most studies with liposome have been
performed, using naturally occurring phospholipids. Depending on the mode of their
preparation three types of liposomes can be formed, viz. multilamellar vesicles (MLVs,
200 to 5000 nm in diameter), small unilamellar vesicles (SUVs, 20-100 nm in diameter)
and large unilamellar vesicles (LUVs, 100-1000 nm in diameted.A variety of drugs can
be encapsulated in liposomes. Highly polar or hydrophilic drugs are entrapped in the internal
aqueous compartments (s), non-polar drugs can be intercalated into the liposomal membrane,
while the amphipathic drugs partition between the membrane and aqueous phase.
Hydrophil~ drug entrapment is maximum in LUVs, while MLVs are more effective as
lipophilic and non-polar drug carriers where the amount of the drug incorporated is directly
proportional to the total mass of the lipid present. Polar drugs are released when the bilayer
is broken, but highly non-polar drugs tend to remain associated with the lipid bilayer unless
it is disrupted by freezing or by permeation9. Also, the release of the drug from liposome
is a function of the ambient pH, ionic interactions, liposomes constituents, physicochemical
properties of the drug and immunological recognition.
The most common route of liposome administration is intravenous injection following
which drugs are rapidly cleared from the blood circulation by the cells of mononuclear
phagocyte system (MPS) (also known as reticuloendothelial system, RES). The MPS
includes, macrophages and macrophage precursors, specialized endothelial cells
surrounding the sinusoids of the liver, spleen, lung and bone marrow and reticular endothelial
cells of lymphatic tissue and of bone marrow. Besides, liposomes can also be taken up by
circulating blood monocytes within the vascular systemlO.Adsorption and/or endocytosis:'\
is the major mechanism of liposome- cell interation. High local concentration of the drug/
at the intracellular site of infection is usually achieved by endocytosis of liposomes".12.
This involves, a) engulf~ent of adsorbed liposomes into vesicles, called phagosomes, by
invagination of the cell membrane, and b) fusion of the phagosome with Iysosomesw ich
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contain degradative enzymes. Drugs resistant to lysosomal digestion are released into the
cell. This can create a high local concentration of drugs at the intracellular sites of infection.
Also, fusion of the outer liposomal membrane with the host cell membrane, and lipid
exchange between liposomes and the cell membranes are two other mechanisms which
may also contribute, although to a lower extent, towards uptake of the liposomal contents
by the cells8.
One of the major constraints in using liposomes as the drug delivery systems has been
their rapid clearance from the blood circulation by the MPS. This may well be exploited
for targeting of drugs to intracellular infections involving the MPS. On the other hand, it
poses a serious limitation for delivering drugs to tissues and cells outside the MPS.
Circulation time of liposomes depends on their size, charge, composition and dose
administered. Large liposomes and negatively charged liposomes are cleared more rapidly
than neutral or positively charged vesiclesl3.14.In the last few years, several efforts have
been made towards the development of more rigid liposomes having better circulation
time15-18.In general,in vivostability and rigidity of the liposomes may be enhanced, to
some extent, by increasing the percentage of long chain saturated phospholipids, viz.
sphingomyelin and sterols in Iiposomes8. It may be further enhanced by including bilayer
rigidfying lipids, such as cholesterol, distearoylphosphatidylcholine and sphingomyelinl9.
An elegant approach of mimicking the outer composition of the red blood cell membrane
in liposomes, by incorporating monosialo-ganglioside, GMl, and hydrogenated
phosphatidylinositol (HPI), resulted in the first generation oflong circulating liposomes2o-21.
This paved the way in designing more clinically acceptable second generation liposomes
which are formed from phospholipids derivitized with hydrophilic polyethylene glycol
(PEG), e.g. PEG-distearoyl phosphatidylethanolamine. These liposomes. more commonly
known as sterically stabilized liposomes (S-liposomes), have been well characterizedl7.22-25.
S-liposomes have low affinity for the cells ofMPS and therefore, show prolonged circulating
periods irrespective of the dose administered, surface charge density and the bilayer
composition24.26.Besides these surface modifications, attempts have also been made to
stabilize the liposomes by introducing the tluorinated core within the membrane27.
Liposomes made of the pertluoroalkylated phosphatidylcholines exhibit higher circulation
times in blood, as compared to conventionalliposomes of similar size comprising distearoyl
phosphatidylcholine (DSPC) or distearoylphoshatidylcholinelcholesterol(DSPC/CH).
Blood clearance rate of the tluorinated liposomes was found to be comparable to that of
the S-liposomes27. More recently, efforts have also been made to combine cyclodextrins
and liposomes into a single system28.
Design of target-specific liposomes
In site-specific targeting of liposomes, usually a ligand (recognition marker), such as
lectin29.3o,carbohydrate31.32,antibody33-36,paptides34.37.38or mannosylated serum albumin
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
4 GRISH C. VARSHNEY and C.M. GUPTA
(neoglycoprotein/9 is attached to the liposomes to make it target specific. The ligand
recognises the complementary sites on the target cell and thus increases the efficiency of
drug delivery. Monoclonal antibodies (MAbs), armed with high degree of specificity
towards certain cell surface antigens, offer the best potential for more precise targeting of
the liposomes (referred to as immunoliposomes) to the desired sites in biophase.1
Liposome-mediated drug delivery in infectious diseases J
One of the major impediments in the effective treatment of the major infectious diseases,
e.g. tuberculosis, leishmaniasis, etc., is the intracellular habitat of the causative organisms
in macrophages. These organisms get protected from the action of many antimicrobial
drugs because of the poor penetration and the poor retention of drug inside the macrophages
or because of the decreased intracellular drug activity due to lower intracellular pHoW.Thus.
liposomes mediated targeting of drugs to infected cells holds great promise for the treatment
of the various intracellular infections, that are major cause of mortality and morbidity in
the third world.
a) Protozoal infections: Liposome-mediated drug delivery has been successfully
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Treatment of leishmaniasis is usually based on the use of leishmanicidal drugs,
principally, pantavalent antimony compounds. such as sodium stibogluconate (Pentostan)4lJ
and meglumine antimoniate (Glucantime).50. Other systemic drugs with proven efficacy in
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the orally administered allopurinol ribonuclcosidcH. High toxicity assuciated with majority
of these drugs poses a serious limitations in their systemic use. For instance, WH055
recommended dose of 20 mg of pentavalent antimonials/kg/day for nearly 30 days, is often
associated with toxic side effect (arthralgias, myalgias and hepatic, cardiac and renal
toxicities). These antimonials, when encapsulatcd in liposomes, proved 200-700-fold more
effective than the free drug when comparcd for single i.v. dosc againstL. clOtWWlII;rodcnt
models.56-5XAlso. following this mode of delivcry, 5-20 fold higher levels of drugs,
compared to that when delivered in free form. could he maintained upto 14 days in blood
circulation.56 A variety of other clinically used drugs in liposomes have also becn tested
againstL.clOfwvan;in animal models. Liposomal amphotericin B has heen shown to exhibit
much improved efficacy and lower toxicity as compared with free drug in experimental
leishmaniasis5\i.c,o.
EI Therapeutic efficacy of the liposomal antileishmanial drugs has been shown to
dramatically increase hy grafting thc cell-specific ligands on thc liposomal surfacc. In this
context. tuftsin-bearing liposomcs havc heen found to be highly efficient (at least 2000
times), as compared to free sodium stihogluconatc, against theL. dOflOva,,;infections in
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mice37. Additionally, pretreatment with these Iiposomes also enhanced the non-specific
resistance of the animals against various infections, including leishmaniasis37. Exclusive
presence of the mannose receptors on the macrophage surface has also been exploited for
the site- specific targeting of liposomal drugs39.43.44.61.Antileishmanial drug, ureastibamine,
encapsulated in mannose-bearing liposomes was found to be more potent than the drug
encapsulated in normal liposomes or the free drug, againstL. donovanin the hamster
model43.In another approach, a toxic antifungal polyene antibiotic, hamycin, encapsulated
in mannosyl serum albumin (neoglycoprotein) containing liposomes was tested in mouse
model of visceral leishmaniasis. This preparation at a dose of 1.5 mg/kg/day when given
for 4 consecutive days completely cured a 45 days old leishmania infection in BALBlc
mice model.44In spite of the higher efficacies of the above formulations in animal models,
their clinical use was hampered mainly for two reasons; (i) down regulation of the
mannoselglucose receptors inL. donovaniinfected macrophages and, ii) the presence of
these receptors even in normal uninfected macrophages62.
Malaria infected erthrocytes have been the other targets for liposomes-mediated drug
delivery36.41.45-48.Encapsulation of the antimalarial drug chloroquine (CHQ) in liposomes
hearing anti-erythrocyte antibody on their surface significantly increased their efficacy
against both CHQ-susceptible and CHQ-resistantPlasmodium bergheiinfections in
mice45-47.The efficacy was further improved by coating CHQ-Iaden liposomes with infected
erythrocyte-specific polyclonal antibodies48.In a recent study, it has been shown that coating
the CHQ laden liposomes with monoclonal antibody (MAb), specifically recognizing the
P. bergheiinfected erythrocytes, significantly controlled not only the CHQ-susceptible but
also the CHQ- resistantP.bergheiinfections in mice36.This clearly demonstrated that the
therapeutic efficacy ofCHQ can be significantly increased by delivering il in target-specific
liposomes, thus paving the way for the treatment of drug resistant infections using the
known drug at lower doses.
b) Bacterial infections:Liposome encapsulation of a variety of drugs has been
successfully tested in treating several bacterial infections, such as those caused by
Mycobacterium tuberculosis, Mycobacterium avium. Salmonella enteritidis. Salmonella
typhimurium, Staphylococcus aureus, Pseudomonas aeruginosa. Klebsiella pneumoniae.
Brucella abortus. Legionella pneumophilaetc63-67.
Aminoglycosides (e.g. streptomycin, gentamycin, sisomycin, amikacin, tobramycin
etc), despile their well documented toxic side effects, remain drugs of choice for the
treatment of bacterial infections, because they acl on both the gram-negative and gram-
positive bacteria, develop only a limited drug resistance during the treatment and do nol
exhibit the inoculum effect66.68.
-.
Experimental murine salmonellosis caused bySalmonella typhimurium.which
resembles the human typhoid causing intracellular bacteria, was effectively treatedwith
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liposomal cephalothin.69. Also, liposome-encapsulted gentamycin was effective against
similar infections 70.Further, streptomycin (1.2 mglkg) upon encapsulation in liposomes
significantly enhanced the survival rate ofS lm nella enteritidis-infected mice, while its
30-times higher dose (40 mglkg) was only marginally effective in free form64.
Using liposomal streptomycin, a 10-fold improvement, when compared to free drug,
in in vitrokilling ofE. coli in 1774.2 macrophages cell line was observed71. In anotheri
vitro study, the liposomes entrapped gentamycin exhibited the enhanced antibacterial
activity against clinically isolated resistant strains ofE. coliandPseudomonas aeruginosa72.
Thus, the liposome-mediated drug deliv~ry may provide an important approach to overcome
bacterial resistance against known drugs.
Effective intracellular killing ofBrucella abortis or Brucella canisha also been
achieved by liposomal streptomycin63 as well as by liposomal gentamycin73.I both the
cases, efficacy of liposomal drugs was much superior when compared to free drugs.
Similarly, a higher efficacy of the liposomal dihydrostreptomycin towards the intracellular
killing ofStaphylococcusaureushas been reported. The liposomal drug was at least 40-times
more effective than the free drug in killing the intraphagosomic S.aureu/4.In fact, the
free drug was not much active against this bacteria.
Liposomal delivery of sisomycin has been attempted in experimental legionnaire's
disease (caused byLegionella pneumophila)in guinea pigs as well as againstin vitro
cultured bacteria in human monocytes75. In thein vitroexperiments, the efficacy was at
least ten times higher for the liposomized drug, as compared to free drug, and an intravenous
administration of this preparation cured 100% of the infected guinea pigs75.
Tuberculosis remains a scourge to m~nkind. Incidence of tuberculosis infection,
particularlyMycobacteril#m avium- M. intracellularecomplex (MAC), has tremendously
increased in the east decade primarily in patients with AIDS3. Rifampicin, isoniazid,
pyrazinamide, thioautazone, p-aminosalicyclic acid, ethambutol and streptomycin are
amongst the major front-line drugs in the treatment of tuberculosis76.77.In spite of their
high antitubercular activity, use of free drugs is limited because of (i) long duration of
chemotherapy (a minimum of 6-12 months) 78and (ii) several side effects 79.80.Combination
of several drugs given at their maximum tolerated doses have not proven effective in
controlling the disseminated disease81. Inherent tendency of liposome to localize in the
phagocytic cells, that also serve as the host ofM. tuberculosis.has been well exploited for
"passive targeting" of liposomal drugs.
Liposomes mediated drug delivery for various antitubercular drugs has been attempted,
using animal models as well as thein vitrosystems. Liposomal-streptomycin exhibited
several fold higher concentration in liver and spleens of infected animals, thus reducing
the bacterial load significantly, ascompared to that achieved with free drugH2.83.Interesti ngly,
"
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accumulation of drug in lung and kidney was not dependent on its formulation, suggesting
that the free and riot liposomal streptomycin accumulates is mouse kidney. Efficacy of
liposomal streptomycin has also been tested in mouse model of nontuberculosis
mycobacterial (MAC) infections84.85.These studies have clearly shown the reduced bacterial
growth in liver .and spleen compared to untreated controls86or the greater inhibition of the
bacterial growth with liposomal streptomycin, compared to free drug85.
Rifampin (RFP) has been extensively used as a potent antitubercular drug. It exhibits
little or no cross-resistance with other antimicrobial drugs87. Although, the drug is safer,
yet the high excretion rate necessitates daily administration in high doses76.This results in
serious toxic side-effects88. Liposomized-RFP given at 10 mglkg dose has been shown to
be more effective than the free drug in controlling the tuberculosis infection89. Similar
effect was seen when RFP was administered in combination with isoniazid in liposomes90
Based on the observation that the intermittent but not the continuous treatment with Lip-RFP
was around 50 folds more effective than the free drug led to the conclusion that Lip-RFP
is preferentially localized in macrophages/monocytes89. A change in distribution pattern of
Lip-RFP was observed in various tissues of tuberculosis infected animals as compared to
normal animals. Comparatively, a higher liposome concentration in lungs, kidneys and
blood was observed in tuberculosis-infected animals, whereas in uninfected animals
Lip-RFP accumulated mainly in liver. 14Further, liposomal targeting ofRFP to macrophages
was significantly enhanced by incorporating tuftsin in the bilayer of Lip-RFP, RFP delivered
twice weekly for 2 weeks in tuftsin- bearing liposomes was at least 200 times more effective
than the free drug in lowering the load of lung bacilli in infected animals89.
Liposome encapsulated gentamycin was tested for controlling the disseminated MAC
infection and its efficacy was compared to that of free gentamycin91. The encapsulated
drug was found to be significantly more effective than the free drug alone in reducing the
viable cell counts in mouse spl~n, liver and lungs. Based on these promising results, phase
11I1safety and dose finding study was undertaken using TLC G- 65, a liposome-encapsuiated
gentamycin92.TLCG-65, at different doses, was administered twice weekly for 4 weeks to
AIDS patients with MAC infection. This treatment resulted in more than 75% reduction
in MAC colony counts in blood92.
Considerable attention has been focused on the use of liposomal amikacin in the
treatment of experimental MAC infection.86.93Treatment with liposome encapsulated
amikacin was substantially more effective in infected liver, spleen and kidney tissue than
with equal amount of free drug given intravenously86.93. A single injection of liposome
encapsulated amikacin resulted in the persistence of its antimicrobial activity for at least
five weeks, particularly in liver and kidneys86.
c) Fungal infections: Fungal infections are a major cause of mortality of
immunocompromised individuals, such as patients of cancer, renal transplant, AIDS etc.94.95
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Liposome-based drug delivery system has been used in the treatment of several fungal
infections, like histoplasmosis, cryptococcosis, aspergillosis and candidiasis96.99,Polyene
antibiotics, like amphotericin- B(Amp-B), nystatin, hamycin, etc., are potent antifungal
drugs96.lOO.IOI.Among these, Amp-B has been the most widely and successfully tested in
treatment of the fungal infections. The drug interacts with ergosterol/cholesterol in the
fungal cell memberanes, thus generating transmembrane channels that permit the leakage
of vital ions and metabolites. The drug, specially at higher doses, is highly nephrotoxic.
Efficacy and associated toxicity of Lip-Amp-B depends on several physical factors,
like presence or absence of sterols, phospholipid type, lipid ratio and size ofliposomesI02-103.
Due to lower toxicity of Lip-Amp-B, higher doses of the drug are tolerated, resulting in
increased therapeutic index. This has been demonstrated in experimental animals97.98as
well as in human trialslO4-I06,A follow up of 46 patients who received Lip-Amp-B therapy
revealed that 25 patients with a variety of fungal infections were classified as complete
responders to the liposomal drug 106.Similar clinical improvement was noticed using
Lip-Amp-B in another study conducted on cancer patients with frugal infectionslO7.
Majority of the fungal infections in cancer patients are caused byCandida albicanslO8
Liposomal encapsulation decrease the toxicity associated with the administration of Amp-B
while maintaining its therapeutic efficacy in experimental candidiasis98,109.J10.A ten-fold
increase in the dose was achieved with Lip-Amp-B without any apparent toxicity. Unlike
free Amp B, Lip-Amp-B fully maintained its effectiveness even at doses of 5-20 mglkg,
providing 100% survival of mice 110.Recently, it has been shown that the Lip-Amp-B
aerosol, given twice-weekly upt03 weeks, is highly effective in treating the lethal infection
of C.albicansin mice. III Aerosolized Lip-Amp-B was also found effective in treatment
of the mice infected intranasally withCryptococcus neoformansll2.An important
observation emanating from the above studies was that Amp-B delivered in this manner
to lungs was capable of diffusing to distant organs at therapeutic levels, thus curing the
systemic infections.
In a murine model of cryptococcosis, which included intraperitoneal, intratracheal, or
intracerebral challenges with C.neoformans,the efficacy of Lip-Amp B was compared
with that of micellar Amp-B deoxycholate suspension (ABDS, Fungizone). Doses of
Lip-Amp-B formulation that were five fold higher than the maximum tolerated dose of
ABDS, were found to be more efficacious regardless of the site of inoculation of the
organism9; Amp-B colloidal dispersion (ABCD) is another lipid based complex, consisting
of Amp-B and cholesteryl sulfate in a 1:1 molar ratio, and has been proposed as an equally
but less toxic alternative to ABDS, for the treatment of disseminated cryptococcosisl13.
Aspergillosis is one of the most common airborne systemic fungal infections which
can be fatal for immunodebilitated patients 114.Lip-Amp-B has been used to control
aspergillosis in experimental animalslJ5 and humans I16.Lip-Amp-B at a dose of 0.5 mg/kg
~
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bodyweight is more effective & less toxic than the free drug in the treatment of experimental
aspergillosis in BLAB/c micel15.Further, it was observed that inclusion of cholesterol into
phosphatidylcholine liposomes increased the LD50 of AMP-B from 5.3. to 8.5 mg/kg body
weightll7. Moreover, the efficacy of liposomal AMP-B or hamycin could be further
improved by grafting on the liposomes surface mannose99 or tuftsin38.
Coda
Targeting drugs specifically to diseased cells in the body has been one of the coveted
goals in clinical therapy. Liposomes so far constitute the best known system and have been
widely used in the delivery of several kinds of drugs. The last about ten years have seen
a spurt in the efforts towards the improv~ment of this mode of drug delivery. Liposomes
can now be designed with more circulation time and commercial acceptability. It is now
clear that passive targeting of liposomes encapsulated drugs effectively cures MPS
associated intracellular infections. This has led to the successful use of liposomal drugs in
human patients with drug resistant visceral leishmaniasis, fungal infections and bacterial
diseases. However, clinical data for liposome mediated drug delivery in infections outside
MPS is sparse. Making liposomes more specific to diseased cells, without affecting normal
cells, is another area demanding serious attention. Using parasite infected cell surface
specific monoclonal antibodies for coating the drug laden liposomes may further provide
specificity to this mode of drug delivery.
Acknowledgement
We are grateful to Ms. Apollina Goel and Ms. Amita Sharma for their help in preparing
the manuscript. This is a communication no. 030/95 from Institute of Microbial Technology,
Chandigarh, India.
References
I. Gibbon, A. (1992)Science257 : 1036.
2. Ashford, R.W., Desjeux, P. & DeRaaft, P. (1992)Para.fitol. Today8 : 104.
3. Bloom, B.R. & Murray, CJ.L. (1992)Science257 : 1055.
4. Lederberg, J. (1993)Trends Microbiol.1 : 43.
5. Bangham, A.D., Standish, M.M. & Watkins, J.C. (1965)J. Mol. Biol.13 : 238.
6. Gregoriadis, G. & Florence, A.T. (1993)Drug.f45: 15.
7. DeGier, J., Mandersloot, J.S. & Vandeenen, L.L.M. (1986)Biochim. Biophys. Acta860: 666.
8. Ostro, ~J. (1987) Sci.Am.256: 102.
9. Stamp, D. & Juliano, R.L. (1979)Can. J. Physiol. Pharmcol.57 : 535.
10. Poste, G. (1983)Biol. Cell.47: 19.
II. Ostro, MJ., Giacomoni, D., Lavelle, D., Pasetron, W. & Dray, S. (1978)Nature274: 921.
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
Dimitriadis, GJ.(l978)Nature274: 923.
Mehta, K., Lopez-Berestein, G., Hersh, E.M., Juliano, R.L. (1982)Reticuloendothdial Soc.32 : 155.
Orozco, L.C., Forero, M., Wasserman, M. & Ahumada, U. (1990)Tubercle,71 : 209.
Allen, T.M., Hansen, C. & Rutledge, J. (1989)Biochl!lII.Biophys. Acta981: 27.
Gabizon, A. & Papahadjopoulos, D.(l992)Bi(l(:helll. Biophys. Acta1103: 94.
Allen, T.M. (1994)Trends Pharmacol. Sci.15: 215.
Bakker-Woudenberg, I.AJ.M., Storm, G. & Woodle, M.C. (1994)J. Drug Targeting2: 363.
Robbins- Roth, (1991)Bioventure View6 : I.
Allen, T.M. & Chonn, A. (1987)FEBS Lett.223: 42.
Gabizon, A. & Papahadjopoulos, D. (1988)Proc. Natl. Acad. Sci. USA8S: 6949.
Klibanov, A.L., Maruyaa, K., Torchilin, V.P. & Huang, L. (1990)FEBS Lett.268: 235.
Allen, T.M., Hansen, C., Martin, F., Redemann, C. & Yau-Young, A. (I 991)Biochl!lII.Biophys. Acta 1066
: 2.
Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Mathay, K.,Huang, S.K., Lee, K.D., Woodle,
M.C., Lasic, D.D., Redemann, C. & Martin, EJ. (1991)Proc. Natl. Acad. Sci. USA88: 11460.
Blume, G. & Cevc, G. (1993)Biochem. Biophys. Acta1146 : 157.
Allen, T.M. & Hansen, C. (1991)Biochem. Biophys. Acta1068: 133.
Santaella, C., Frizard, F., Vierling, P. & Riess, J.G. (1993)FEBS Lett.3 : 481.
McCormack, B. & Gregoriadis, G. (1994)Int. J. Pharmaceutic,f112: 249.
Hutchinson, FJ. & Jones, M.N. (1988)FEBS Lett.234: 493.
Bagdanov, A.A., Gordeeva, L.V., Torchilin, V.P. & Margolis, L.B. (1989)Exp. Cell. Res.181 : 326.
Ghosh, P. & Bachhawat, B.K. (1980)Biochem. BiophY,f. Acta632: 562.
Das, N., Bachhawat, B.K., Mahato, S.B. & Basu, M.K. (1987)Biochem. J.247: 359.
Singhal. A. & Gupta, C.M. (1986)FEBS Letts.201 : 321.
Singhal, A., Bali, A. & Gupta, C.M. (1986)Biochem. Biophy.f. Acta.880: 72.
Senior, J. & Gregoriadis, G. (1989)Bioch"III. Biophy.f. Acta1003: 58.
Owais, M., Varshney, G.C., Choudhury, A., Chandra, S. &.Gupta, C.M. (1995)Antimicrob. Agent.f
Chemmher.39 : 180.
Guru, P.Y., Agrawal, A.K., Singha, U.K., Singhal, A. & Gupta, C.M. (1989)FEBS Left.245: 204.
Owais, M., Ahmad, I., Krishnakumar, B., Jain, R.K., Bacchawat, B.K., & Gupta. C.M. (1993)FEBS. Lett.
326 : 56.
Chakraborty, P., Bhaduri, A.N. & Das, P.K. (1990)Biochem. Biophys. Re.f. Commun.166: 404.
Scwab,lC. & Mandell, G.L. (1989)I"fect. Dis. Clin. North Am.3: 461.
Alving, C.R. (1986)Parasitol. Today2: 101.
Dolan, T.F., Hunter, C.A.. Laakso. T.. Coombs. G.H., Baillie, AJ., Sjarnkvist, P. & Sjoholm, I. (1989) in
Lei.fhlllania.fis- Ihe currenl status& new .ftralegire.f.for control,ed. Hart, D.T.. Sericr, A.. Vol. 163, p.
793.
Medda,S., Mukherjee,S., Das, N.. Naskar, K., Mahato, S.B. & Basu, M.K. (1993)Biotechnol. Appl.
Biochem.17: 37.
. 12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
I
43.
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
Kole, L., Sarkar,K., Mahato, S.B. & Das, P.K. (1994)Biochem. Biophys. Res. Commun.200: 351.
Agrawal, A.K., Singhal, A. & Gupta, C.M. (1987)Biochem. Biophys. Res. Commun.148 : 357.
Peeters, PAM., Huiskamp, C.W.E.M., Eling, W.M.C. & Crommelin, DJ.A. (1989)Parasitology98 :
381.
Chandra, S., Agarwal, A.K. & Gupta, C.M. (l991).r.Bio w'i16 : 137.
Singh, A.M., Owais, M. & Varshney, G.C. (1993)Ind. J. Biochem. Biophys.30: 411.
Herwaldt, B.L. & Berman, J.D. (1992)Am. J. Trop. Med. Hyg.46: 296.
World Health Organization (1991)Tropial disease-Progress in research.TOR Tenth Programme Report,
WHO, Geneva, 1989-90, p. 79.
Marsden, P.O. & Jones, T.C. (1985) inLeishmaniasis.ed. Chang, K.P., Bray, RS., Elsevier, London, p.
183. .
Thakur, C.P., Kumar, M. & Pandey, A.K. (1991)Am. J. Trop. Med. Hyg.45: 435.
Saenz, RE., Paz, H. & Berman, J.D. (1990)Am. J. Med.89 : 147.
Chunge, C.N., Gachihi, G., Muigai, R, Wasunna, K., Rashid, I.R., Chulay, J.D., Anabwani,G., Oster,
C.N., & Bryceson, A.D.M. (1985)Trans. R. Soc. Trop. Med. Hyg.79: 715.
World Health Organization (1984)The Leishmaniasis.Report of a WHO Expert Committee, Technical
Report Series No. 70 I, WHO, Geneva.
Black, C.D.V., Watson, G.J. & Ward, RJ. (1977)Tran.f. R. Soc. Trop. Med. Hyg.71 : 551.
Alving, C.R., Steck, E.A., Chapman, W.L. Jr., Waits, V.B., Hendricks, L.D., Swartz, G.M. Jr. & Hanson,
W.L. (1978)Proc. Natl. Acad. Sci. USA75 :959.
New, R.R.C., Chance, M.L., Thomas, S.C. & Peters, W. (1978)Nature272: 55.
New, R.R.C., Chance, M.L. & Health, S. (1981)J. Antimicrob. Chemoth.8: 371.
Berman, J.D., Hanson, W.L., Chapman, W.L., Alving, C.R. & Lopez- Berestein, G. (1986)Antimicrob.
Agents. Chemother.30: 847.
Sen, R., Sarkar, K. & Das, P.K. (1993)J. Infec. Dis.168: 994.
Basu, N., Sett, R & Das, P.K. (1991)Biochem. J.277: 451.
Fountein, M.W., Weiss, S.J., Fountein, A.G., Shen, A. & Lenk, A.P.(l985)J.lnfect. Dis.152: 529.
Tadakuma, T., Ikewaki, N., Yasuda, T., Tsufsumi, M., Saito, S. & Saito, K. (1985)Antimicrob. Agent
Chemather.28 : 28.
Bermudez, L.E.M., Yau-Young, A.O., Uu, J.P., Cogger, J. & Young, L.S. (I99O)J. nfect. Dis.161: 1262.
Karlowsky, J.A. & Zhanel, G.G. (1992)Clin. Infect. Dis.15: 654.
Bakker-Woudenberg, LA.J.M., Lokerse, A.F., Tenkate, M.T., Melissen, P.M.B., Vianen, W.V. &
VanEtten, E.W.M. (1993)Eur. J. Clin. Microbial. Infect. Dis. Suppl.11 : 61.
Zhanel, G.G. & Ariano, RE. (1992)Renalfailure14: I.
Desiderio, J.V. & Capbell, S.G. (1983)J. Infect. Dis.148: 563.
Swenson, C.E., Stewart, K.A., Hammett, J.L., Fitzsimmons, W.E. & Ginsberg, RS. (1990)Antimicrob.
Agents. Chemother.34 : 235.
Stevenson, M., BailJie, A.J. & Richards, RM.E. (1983)Antimicrob. Agents Chenwther.24 : 742.
Nacucchio, M.C., Gatto-Bellora, MJ., Sordelli, D.O., 0' Aquino, M. (1988)J. Microencapsul.5 : 303.
Dees, C., Fountain, MW., Taylor, J.R. & Schultz, R.D. (1985)Vet. Immunol. Immunopathol.8: 171.
.44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54..-
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
Bonventre, P.F. & Gregoriadis, G. (1978)Antimicrob. Agenrs Chemother.13 : 1049.
Sunamoto, J., Goto, M., Iida, T., Hara, K., Saito, A. & Tomonaga, A. (1984) inReceprormediated targeting
of drugs.eds. Gregoriadis, G., Poste, G., Senior, J. & Trouet, A., Plenum Press, New York, p. 359.
Raleigh, J.W. (1984) inThe Mycobacteria: a source book.eds. Kubica, G.P. & Wayne, L.G., Microbiology
Series, Library of congress cataloging in publication data, Vol. 15, p. 1007.
I
Mitchison, D.A., Ellard, G.A. & Grosset,J. (1988)Br. Med. Bull.44: 757.
Chaulet, P. (1989)World Health Forum10: 16. ,
Girting, D.I. (1978)Tubercle59: 13.
Zierski, M. & Bek, E. (1980)Tubercle61: 4l.
Agins, B.D., Berman, D.S., Spicehandler, D.E., Sadr, W., Simberkoff, M.S. & Rahal, U. (1989) J.Infect.
Dis.159 : 784.
Vladimirsky, M.A. & Ladigina, G.A. (1982)Biomedicine36: 375.
Ladigina, G.A. & Vladirnirsky, M.A. (1986)Biomed. Pharmacother.40: 416.
Duzgunes, N., Ashtekar, DR, Flasher, D.C., Ghori, N., Debs, R.I., Friend, D.S. & Gangadharam, P.R.J.
(1991) J.Infect. Dis.164 : 143.
Ashtekar, D., Duzgunes, N. & Gangadharam, P.R.I. (1991) J.Antimicrob. Chemother28 : 615.
Duzgunes, N., Perumal, V.K., Kesavulu, L., Goldstein, J.A., Debs, R.I. & Gangadharan, P.R.I. (1988)
Anrimicrob. Agenrs Chemother.32 : 1404.
Konno, K., Oizumi, K., Ariji, F., Yamaguchi, J. & Oka, S. (1973)Am. Rev. Resp. Dis.107: 1002.
Raleigh, J.W. (1972) Am.Rev. Resp. Di.f.105: 397.
Agarwal, A., Kandpal, H., Gupta, H.P., Singh, N.B. & Gupta, C.M. (I 994)Anrimicrob. Agenrs. Chemother.
38 : 588.
Orozco, L.C., Quintana, F.O., Beltran, RM., Moreno, I.D., Wasserman, M. & Rodriguez, G. (1986)
Tubercle67 : 9l.
Klemens, S.P., Cynamon, M.H., Swenson, C.E. & Ginsberg, R.S. (1990)Antimicrob. Agents Chemother.
34:%7.
Nightingale, S.D., Saletan, S.L., Swenson, C.E., Lawrence, A.I., Watson, D.A., Pilkiewicz, F.G.,
Silverman, E.G. & Cal, S.X. (1993)Anrimicrob. Agents Chemother.37 : 1869.
Bermudez, L.E.M., Wu, M. & Young, L.S.(l987)J.lnfect. Di.f.156: 510.
Korting, H.C., Ollert, M., Georgii, A. & Froschl, M. (1988) J.Clin. Microbiol.26 : 2626.
Meunier, F. (1988) inClinical approach to infection in the compromised host.eds. Rubin, R.H. & Young,
L.S., 2nd Ed., New York, Plenum Press, p. 193.
Taylor, R.L., Williams, D.~., Craven, PC., Graybill, J.R., Drutz, D.J. & Magee, W.E. (1982)Am. Rev.
Resp. Dis.125: 610.
Graybill, J.R, Craven, P.C., Taylor, RL., Williams, D.M. & Magee, W.E. (1982)J.Infect. Dis.145: 748.
Tremblay, C., Barza, M., Fiore, C. & Sroka, F. (1984)Anrimicrob. Agenrs Chemother.26 : 170.
Ahmad, I., Sarkar, A.K. & Bacchawat, B.K. (l991)J.Clin Biochem. Nutr.10: 17l.
Juliano, R.L., Lopez-Berestein, G., Hopfer, R., Mehta, R., Mehta, K. & Mills, K. (1985)Ann. N. Y.Acad.
Sci.446 : 390.
Mehta, R.T., Mcqueen, T.J., Keyhani, A. & Lopez-Berestein, G. (1991)J.Infect. Dis.164: 1003.
Lopez-Berestein, G. (1988)Ann. N. Y.Acad. Sci.544 : 590.
74.
75.
76.
77.
78.
79.
80.
8l.
82.
83.
84.
85.
86.
87.
88.
89.
90.
9l.
92.
93.
94.
95.
96.
97.
98.
99.
100.
1Ol.
102.
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
103. Szoka, F.C., Milholland, D. & Barza, M. (1987)Antimicrob. Agents Chemother.31 : 421.
104. Lopez-Berestein, G., Fainstein, V., Hopefer, R., Mehta, K., Sullivan, M.P., Keating, M., Rosenblum, M.G.,
Mehta, R., Luna, M., Hersh, E.M., Reuben, J., Juliano, R.L. & Body, G.P. (1985)J. Infect. Dis.151 :
704.
105. Lopez-Berestein, G., Body, G.P., Frankel, L.S. & Mehta, K. (1987)J. Clin. Oncol.5 : 310.
106. Lopez-Berestein, G., Body, G.P., Fainstein, V., Keating, M., Frankel, L.S., Zeluff, B., Gently, L. & Mehta,
K. (1989)Arch. Intern. Med.149: 2533.
107. Sculier, J.P., Coune, A., Meunier, F., Blassine, c., Laduron, C., Hollaen, C., Collette, N., Heyman, C. &
Klustersky, J. (1988)Eur. J. Cancer Clin. Oncol.24: 527.
108. Bodey, G.P. (1977)CurroProb. Cancer.1 : 3.
109. Lopez-Berestein, G.,Mehta, R., Hopfer, R.L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh,
E.M. & Juliano, R. (1983)J. Infect. Di.f.147: 939.
110. Gondal, J.A., Swartz, R.P. & Rahman, A. (1989)Antimicrob. Agents Cherrwther.33 : 1544.
Ill. Gilben, B.E., Wyde, P.R., Lopez-Berestein, G. & Wilson,S.Z.(1994)Antimicrob. Agenu Chemother. 38
: 356.
112. Gilben, B.E., Wyde, P.R. & Wilson,S.Z.(1992)Antimicrob. Agent.f Cherrwther.36 : 1466.
113. Hostetler, J.S., Clemons, K.V., Hanson, L.H. & Stevens, D.A. (1992)ntimicrob. Agents Chemother. 36
: 2636.
114. Medoff, G., Brajtburg, J., Kobayashi, G.S. & Bolard, J. (1983)Annu. Rev. Pharrrwcol. Toxicol.23 : 303.
115. Ahmad, I., Sarkar, AX & Bacchawat, B.K. (1989)Indian J. Biochem. Biophy.f.26 : 351.
116. Weber, S.R. & Lopez-Berestein, G. (1987)Larynego.fcope97 : 937.
117. Ahmad, I., Sarkar, AX & Bacchawat, B.K. (1990)Biotech. Appl. Biochem.12 : 550.
Proc.Nalt.Acad.Sci.(India) LXVI (Sect.B), 1-13 (1996)
